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Summary
Background: We compared the clinical utility of additional intravenous immune glob-
ulin (IVIG) therapy with the clinical utility of steroid pulse therapy in patients with
IVIG-resistant Kawasaki disease.
Methods: We enrolled 164 patients with Kawasaki disease who were treated with a
single dose of IVIG (2 g/kg) and aspirin (30mg/kg per day). Twenty-seven of these
patients (16%) were resistant to the initial IVIG treatment. We compared the effec-
tiveness of treatment strategies for the initial IVIG-resistant 27 patients, 14 of these
patients were treated with additional IVIG therapy, and the other 13 patients were
treated with steroid pulse therapy (methylprednisolone 30mg/kg per day for 3 days).
Results: Three patients in the group receiving additional IVIG treatment had coronary
artery aneurysms (21.4%), no patients had coronary artery aneurysm in the steroid
pulse therapy group; the difference in the incidence of coronary artery aneurysm
was not statistically signiﬁcant. The duration of high fever after additional treatment
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in the steroid pulse therapy group (1± 1.3 days) was signiﬁcantly shorter than that
in the additional IVIG treatment group (3± 2.4 days; P < 0.05). The medical costs
were signiﬁcantly lower in the steroid pulse therapy group than in the additional IVIG
treatment group.
Conclusion: Steroid pulse therapy was useful to reduce the fever duration and medical
costs for patients with Kawasaki disease. Steroid pulse therapy and additional IVIG
treatment were not signiﬁcantly different in terms of preventing the development of
coronary artery aneurysm.
e of
I
A
d
s
a
d
d
(
o
I
t
I
A
t
T
r
m
K
w
1
d
a
H
2
d
2
s
c
p
e
v
i
C
In calculation of medical cost the hospitalization© 2008 Japanese Colleg
reserved.
Introduction
Kawasaki disease (KD) is an acute febrile illness
characterized by mucosal inﬂammation, skin rash,
and cervical lymphadenopathy, and is observed
most often in children younger than 4 years of
age [1]. This is an acute vasculitis syndrome of
unknown etiology that affects primarily small- and
medium-sized arteries, particularly the coronary
artery [2]. Treatment for KD has been the subject
of many studies [3—6]. Recently, the adminis-
tration of high-dose intravenous immune globulin
(IVIG) has been observed to reduce both the
duration of fever and the incidence of coronary
artery aneurysms (CAA) when given within a few
days of disease onset [7—9]. Nonetheless, approx-
imately 10—20% of patients have persistent or
recurrent fever despite IVIG treatment [3,6,10,11].
The risk of CAA is increased in these patients,
and there have been few studies on the opti-
mal management of such cases [3,6,10,11]. In
a recent small-randomized trial, Hashino et al.
compared the efﬁcacy of additional IVIG treat-
ment with the efﬁcacy of steroid pulse therapy
for IVIG treatment-resistant KD patients [3]. The
aim of the present study was to compare the
effectiveness of additional IVIG treatment with
that of steroid pulse therapy for KD patients
who showed resistance to initial IVIG treat-
ment.
Methods
Patients
One hundred and sixty-four patients, ranging in
age from 2 months to 10 years, were included
in the study. They were treated at Kitasato Uni-
versity, Ebina General Hospital, and Sagamihara
Kyodo Hospital between April 2004 and May 2007.
The diagnosis of KD was made according to crite-
ria established by the Japanese Kawasaki Disease
Research Committee [12].
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nitial treatment
ll patients were initially treated with a single
ose of IVIG (2 g/kg per day) in a single infu-
ion over a 24-h period and were administered
spirin orally (30mg/kg per day) within the ﬁrst 9
ays of the onset of fever. We deﬁned a respon-
er as a patient who showed resolution of fever
<37.5 ◦C) and a fall in C-reactive protein (CRP)
f more than 50% within 36—48 h after initial
VIG treatment [3,12—14]. These patients were
reated with steroid pulse therapy or additional
VIG.
dditional IVIG treatment and steroid pulse
herapy
wenty-seven patients (16%) showed no clinical
esponse at 36—48 h after initial IVIG treat-
ent. Thirteen non-responders were treated at
itasato University Hospital, and these patients
ere treated with steroid pulse therapy (group
: methylprednisolone 30mg/kg per day for 3
ays). The remaining 14 patients were treated
t Ebina General Hospital and Sagamihara Kyoudo
ospital with additional IVIG treatment (group
). There were no signiﬁcant differences in gen-
er, age, or duration of illness between the
groups (Table 1). During steroid pulse infu-
ion and IVIG treatment patients underwent
ontinuous cardiac monitoring and their blood
ressure was determined every 30min. Frequent
valuations were made after the infusion until
ital signs were stable and within normal lim-
ts.
alculation of medical costasic charge, clinical test (laboratory test, electro
ardiograph, echocardiography, etc.) costs, dis-
osal costs, cost of procedures and cost of drugs
ere included. The medical costs were calculated
rom admission to discharge.
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Table 1 Age, gender, and duration of illness on admission
Group 1 Group 2 P
Age 1 year 2 months± 1 year 5 months 2 years 9 months± 2 years 0 month NS
Gender (male:female) 7:5 9:4 NS
grou
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2Duration of illness 5± 0.3 days
Group 1, steroid pulse therapy group; group 2, IVIG treatment
tatistical analysis
ll data are expressed as the median± S.D.
ann—Whitney’s U-test was used for the two-way
omparison of data. Values were considered signif-
cantly different at P < 0.05.
esults
esults of treatment
ne hundred and sixty-four sequential patients
ere treated with IVIG (2 g/kg) immediately
fter being diagnosed with KD. One hundred and
hirty-seven of these patients (84%) were clin-
cal responders to the initial treatment, and
one of these patients showed coronary artery
bnormalities. However, the remaining 27 patients
16%) showed no clinical response. These patients
ere treated with either steroid pulse ther-
py (methylprednisolone 30mg/kg per day for 3
ays) or additional IVIG (2 g/kg). The 13 IVIG-
esistant patients at Kitasato University Hospital
ere treated with steroid pulse therapy (group
), and the 14 IVIG-resistant patients at Ebina
eneral Hospital and Sagamihara Kyodo Hospital
ere treated with additional IVIG treatment (group
) within 36—48 h after initial IVIG treatment.
lthough 2 patients developed bradycardia in the
L
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Table 2 Illness day and laboratory data on additional trea
Group 1
Illness day 7 ± 1.3
WBC (l) 12,500 ± 1,029
Neutrophils (%) 67 ± 10
Ht (%) 32 ± 2
Platelets (×104) 32 ± 15
CRP (mg/dl) 4.3 ± 1.7
AST (IU) 35 ± 16
ALT (IU) 28 ± 60
Na (mequiv./l) 134 ± 2.5
Albumin (mg/dl) 4 ± 2.4
Data are the mean± S.D. WBC, white blood cells; Ht, hematocrit; C
alanine aminotransferase.
Group 1, steroid pulse therapy group; group 2, IVIG treatment grou4± 1.3 days NS
p.
teroid pulse group, these cases improved sponta-
eously.
ncidence of CAA
AA occurred in 3 patients (21.4%) in the additional
VIG treatment group (group 2). One patient had a
iant coronary aneurysm, and the other 2 patients
ad small aneurysms. No patients had CAA in the
teroid pulse therapy group (group 1). There was no
tatistically signiﬁcant difference in the incidence
f CAA between the 2 groups.
uration of fever
o signiﬁcant difference was found between the
groups with regard to illness days before addi-
ional treatment (Table 2). The duration of fever
>37.5 ◦C) after additional treatment in patients
reated with steroid pulse therapy (1± 1.3 days)
as signiﬁcantly shorter than that in patients
reated with additional IVIG treatment (3± 2.4
ays; P < 0.05). A signiﬁcant difference was found
n the total duration of fever between the 2 groups
8± 2.1 days in group 1 versus 11± 2.0 days in group
; P < 0.05).aboratory data
aboratory data on admission and after initial treat-
ent are shown in Tables 2 and 3. Except for
tment
Group 2 P
8 ± 2.4 NS
10,700 ± 3,769 NS
64 ± 16 NS
33 ± 2 NS
50 ± 15 <0.05
5.9 ± 4.0 NS
34 ± 21 NS
26 ± 44 NS
133 ± 2.6 NS
3.9 ± 0.4 NS
RP, C-reactive protein; AST, aspartate aminotransferase; ALT,
p.
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Table 3 Laboratory data on admission
Group 1 Group 2 P
WBC (l) 14,200 ± 5,435 12,000 ± 3,368 NS
Neutrophils (%) 77 ± 24 72 ± 9 <0.05
Ht (%) 32 ± 2 30 ± 3 NS
Platelets (×104) 31 ± 11 31 ± 16 NS
CRP (mg/dl) 7.3 ± 9.8 9.5 ± 6.0 NS
AST (IU) 40 ± 533 32.5 ± 75 NS
ALT (IU) 26 ± 207 26 ± 158 NS
Na (mequiv./l) 133 ± 1.9 132 ± 22.5 NS
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Data are the mean± S.D. WBC, white blood cells; Ht, hematoc
alanine aminotransferase. Group 1, steroid pulse therapy grou
neutrophils, no signiﬁcant difference was found
between the 2 groups with regard to laboratory
data on admission (Table 3). In the 36—48 h after
initial treatment, except for platelet count, no sig-
niﬁcant difference was found in laboratory data
between the 2 groups (Table 2). However, 36—48 h
after additional treatment, the CRP level in group
1 patients (0.6± 1.4mg/dl) was signiﬁcantly lower
than that in group 2 patients (1.7± 4.9mg/dl;
P < 0.05).
Medical cost and duration of hospital stays
The medical costs for the 2 therapies were cal-
culated to be 290,610± 57,477 yen (group 1) and
918,300± 61,405 yen (group 2), respectively. The
medical costs of patients treated with steroid pulse
therapy were signiﬁcantly lower than those of
patients treated with additional IVIG treatment
(P < 0.05). There was no signiﬁcant difference in
hospital stay in patients treated with steroid pulse
therapy and that in patients treated with additional
IVIG (14.5± 2.0 days group 1 versus 12± 2.1 days
group 2).
Discussion
CAA
There was no statistically signiﬁcant difference in
the incidence of CAA between the 2 groups. In
the present study, 3 patients who were treated
with additional IVIG therapy developed a CAA. How-
ever, no patients treated with steroid pulse therapy
had a CAA. Steroid pulse therapy, which has var-
ious anti-inﬂammatory effects, is widely used for
the clinical treatment of inﬂammatory and autoim-
mune disorders [3—6,15,16]. Both IVIG treatment
and steroid pulse therapy may inhibit the produc-
tion of cytokines that act in the reconstruction of
the inﬂamed coronary artery wall. Makata et al.
w
p
t
o
i4.1 ± 1.2 NS
RP, C-reactive protein; AST, aspartate aminotransferase; ALT,
oup 2, IVIG treatment group.
reviously reported that steroid therapy resulted
n a more wide inhibition of inﬂammatory cells
ompared with immunoglobulin treatment in cul-
ured cells setting [17]. However, it remains unclear
hether steroid pulse therapy affects the coronary
rtery wall, particularly in the long-term [18—20].
he long-term effect of steroid pulse therapy on
he coronary arteries (i.e., the incidence of regres-
ion, the occurrence of stenosis or obstruction, the
evelopment of aneurysms, and endothelial func-
ion) has not been clariﬁed. Further investigation
f the long-term outcome of the coronary arteries
n KD patients treated with steroid pulse therapy
nd estimation of the endothelial function of coro-
ary arteries in KD patients is needed. In addition,
rospective studies will be needed to assess the
ong-term beneﬁts or disadvantages to patients who
eceive steroid pulse therapy or additional IVIG
reatment.
linical implications
previous meta-analysis reported on the effective-
ess of steroids in KD treatment [21]. However,
ewburger et al. reported that the effectiveness
f steroid pulse therapy in initial treatment is
ot recognized [22]. In the present study, we ﬁrst
emonstrated the clinical utility of steroid pulse
herapy as a second treatment in IVIG treatment-
esistant KD patients. The duration of fever after
dditional treatment in the steroid pulse therapy
roup was signiﬁcantly shorter than that in the
dditional IVIG treatment group. In addition, the
edical costs were lower in the steroid pulse ther-
py group. It should be noted, however, that this
tudy employed only a small number of patients and
as not randomized. In the future, a randomized
rospective study involvingmultiple treatment cen-
ers may be necessary to examine the clinical utility
f additional therapy for KD patients resistant to
nitial IVIG treatment.
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teroid pulse therapy was useful to reduce the fever
uration and medical costs in KD patients. Steroid
ulse therapy may be as effective as additional IVIG
reatment to prevent the development of CAA.
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